Lenvatinib resistance mechanism and potential ways to conquer-Reference-Cited by-同舟云学术

Lenvatinib resistance mechanism and potential ways to conquer

Published:2023-04-20 Issue: Volume:14 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Bo Wentao,Chen Yan

Abstract

Graphical AbstractIn this review, we summerized the absorption, distribution, metabolism, excretion of lenvatinib in clinic. The lastest mechanism and potential approches to overcome resistance caused by lenvatinib were supplied.

Funder

Sichuan Province Science and Technology Support Program

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference155 articles.

1. Blood-brain barrier disruption increases amyloid-related pathology in TgSwDI mice;Abdallah;Int. J. Mol. Sci.,2021

2. Lenvatinib: A review in hepatocellular carcinoma;Al-Salama;Drugs,2019

3. Combination of elacridar with imatinib modulates resistance associated with drug efflux transporters in chronic myeloid leukemia;Alves;Biomedicines,2022

4. NADPH oxidases: New actors in thyroid cancer?;Ameziane-El-Hassani;Nat. Rev. Endocrinol.,2016

5. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells;Ao;Biochem. Biophys. Res. Commun.,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Solanum torvum induces ferroptosis to suppress hepatocellular carcinoma;Journal of Ethnopharmacology;2024-12

2. Impact of Type of Lenvatinib Resistance on Prognosis and Second-Line Regimen in Patients with Virus-Associated HCC;Journal of Hepatocellular Carcinoma;2024-08

3. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

4. Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial;Frontiers in Oncology;2024-07-30

5. Sporadic Parathyroid Carcinoma Treated With Lenvatinib, Exhibiting a Novel Somatic MEN1 Mutation;JCEM Case Reports;2024-07-24